How Many Doses Per Vial: Kisspeptin — Reconstitution Guide

Most researchers reconstituting kisspeptin for the first time assume the vial label tells them how many doses they'll get. It doesn't. A 5mg vial can yield anywhere from 10 to 50 doses depending on how you reconstitute it and what dose your protocol requires. We've guided hundreds of research teams through peptide reconstitution. The single biggest source of protocol failure isn't contamination or degraded peptide, it's dose miscalculation at the reconstitution stage.

Our team has worked extensively with high-purity research peptides across cardiovascular, reproductive, and metabolic research protocols. The gap between accurate dosing and wasted peptide comes down to understanding the relationship between vial concentration, reconstitution volume, and target dose. Three variables that interact mathematically, not arbitrarily.

How many doses does a kisspeptin vial contain?

A kisspeptin vial's dose yield is calculated by dividing the total peptide mass (in micrograms) by your target dose per injection (also in micrograms). A 5mg vial reconstituted to 100mcg/mL and dosed at 100mcg per injection yields 50 doses. The same vial dosed at 500mcg per injection yields 10 doses. Vial labeling indicates total peptide mass. Not pre-determined dose count.

The Featured Snippet answers the basic math. What it doesn't cover is why so many researchers calculate correctly but still end up with inconsistent dosing. Or why peptide concentration matters more than most protocols acknowledge. This article covers the reconstitution calculation step-by-step, the volume and concentration variables that determine final dose count, and the storage decisions that either preserve or destroy dose viability across multi-week protocols.

Kisspeptin Vial Concentrations and Standard Research Doses

Kisspeptin-10 (the most commonly used isoform in metabolic and reproductive research) is typically supplied as lyophilized powder in 1mg, 5mg, or 10mg vials. The mass printed on the label represents total peptide content after accounting for peptide purity. A 5mg vial from a reputable supplier contains 5,000 micrograms of kisspeptin-10 at ≥98% purity, verified by HPLC and mass spectrometry.

Research doses vary widely depending on the study design. Human clinical trials investigating kisspeptin's role in reproductive axis regulation have used bolus doses ranging from 0.01 nmol/kg to 6.4 nmol/kg. Which translates to approximately 10mcg to 6,400mcg for a 70kg subject. Animal models (rodent reproductive studies, for example) typically use 100–500mcg per injection. The dose your protocol requires determines how many administrations a single vial supports.

Here's the critical point most guides skip: kisspeptin dose-response curves are steep in many models. A 100mcg dose may produce measurable LH secretion, while a 500mcg dose saturates the response. Splitting a 5mg vial into 50 doses at 100mcg each is only valid if your protocol is designed for that dose range. If your model requires 500mcg per injection, that same vial yields 10 doses. Not 50. The vial doesn't change. The protocol does.

Reconstitution Volume Determines Concentration (And Therefore Dose Yield)

Reconstitution is the step where most dose-count errors happen. Adding 5mL of bacteriostatic water to a 5mg kisspeptin vial creates a 1mg/mL solution (1,000mcg per milliliter). Adding 2mL creates a 2.5mg/mL solution (2,500mcg per milliliter). The peptide mass is identical. The concentration changes based on dilution volume.

Why does this matter? Because your injection volume is typically fixed by equipment constraints. Most insulin syringes used in research settings deliver volumes between 0.1mL and 1mL with reasonable accuracy. If your protocol calls for a 500mcg dose and you've reconstituted to 1mg/mL, you need to inject 0.5mL per dose. If you reconstituted the same vial to 2.5mg/mL, you only need 0.2mL per dose. Same peptide mass, different concentration, different injection volume.

Our experience working with peptide researchers shows this consistently: higher concentrations allow smaller injection volumes, which matters when working with rodent models where injection site tolerance is limited. But higher concentrations also mean less room for pipetting error. A 10mcL pipetting mistake in a 0.2mL injection represents 5% error, while the same mistake in a 1mL injection is only 1% error. There's no universal 'correct' reconstitution volume. The right choice depends on your dose, your model, and your equipment precision.

Calculating Exact Dose Count from Vial Mass and Target Dose

The dose yield formula is simple: Total peptide mass (mcg) ÷ Target dose (mcg) = Number of doses. A 5mg vial contains 5,000mcg. If your protocol requires 250mcg per injection, you calculate 5,000 ÷ 250 = 20 doses. If your dose is 100mcg, you get 50 doses. If your dose is 1,000mcg, you get 5 doses.

Most researchers stop here. They shouldn't. This calculation assumes you can extract and administer the full peptide content with zero loss. In practice, dead volume in the vial and syringe hub means you lose 0.05–0.1mL per reconstituted vial that cannot be drawn into the syringe. If you reconstituted 5mg kisspeptin in 2mL bacteriostatic water to create a 2.5mg/mL solution, losing 0.1mL to dead volume represents 250mcg of unusable peptide. One full dose at 250mcg, or 2.5 doses at 100mcg.

The adjusted formula accounts for this: (Total peptide mass − Dead volume loss) ÷ Target dose = Usable dose count. For a 5mg vial reconstituted in 2mL with 0.1mL dead volume: (5,000mcg − 250mcg) ÷ 250mcg = 19 usable doses instead of 20. It's a small correction, but across a 12-week protocol with multiple vials, ignoring dead volume compounds into significant peptide waste.

What If: Kisspeptin Dosing Scenarios

What If I Reconstitute a 5mg Vial But Only Need 15 Doses?

Reconstitute using a smaller volume to create higher concentration, then store the remaining solution under proper conditions. For 15 doses at 250mcg each, you need 3,750mcg total. Leaving 1,250mcg unused in the vial. If reconstituted in 2mL bacteriostatic water (2.5mg/mL), refrigerate the vial at 2–8°C and use within 28 days. The unused peptide remains stable for the full storage window as long as temperature is maintained and sterile technique is followed during each draw.

What If My Protocol Requires a Dose Between Standard Concentrations?

Adjust reconstitution volume to create a custom concentration that allows convenient injection volumes. For example, a 350mcg dose from a 5mg vial: reconstitute in 2.86mL to create a 1.75mg/mL solution, then inject 0.2mL per dose (0.2mL × 1,750mcg/mL = 350mcg). Custom volumes require precise measurement. Use calibrated pipettes or volumetric glassware rather than estimating with syringe markings.

What If I Accidentally Reconstitute at the Wrong Concentration?

You cannot remove bacteriostatic water once added. The peptide is already in solution. Recalculate your injection volume based on the actual concentration you created. If you intended 2mL but added 3mL, your concentration is now 1.67mg/mL instead of 2.5mg/mL. A 250mcg dose now requires 0.15mL injection volume instead of 0.1mL. The dose count remains the same (total peptide mass hasn't changed), but your per-dose injection volume increases.

What If I'm Splitting a Vial Across Multiple Researchers or Study Arms?

Reconstitute the full vial, then aliquot into sterile cryovials under aseptic conditions. A 5mg vial reconstituted in 5mL yields 1mg/mL. Split into five 1mL aliquots, each containing 1mg peptide (10 doses at 100mcg). Label each aliquot with date, concentration, and vial source. This approach prevents repeated freeze-thaw cycles and cross-contamination risk from multiple users accessing the same vial.

The Blunt Truth About Kisspeptin Vial Dosing

Here's the honest answer: most researchers waste peptide not because they lack the math skills to calculate dose count, but because they treat reconstitution as a one-time decision instead of a protocol-design constraint. A 5mg vial sounds like it should last forever at 100mcg doses. And mathematically it yields 50 doses. But if your protocol runs 8 weeks and you dose twice weekly, you only need 16 doses. The remaining 34 doses sit in the refrigerator degrading past the 28-day stability window, or they get frozen and thawed repeatedly until peptide structure denatures.

The solution is vial-size matching. If you need 20 doses total across your study, order two 1mg vials instead of one 5mg vial. Reconstitute one vial at a time, use it fully within the stability window, then reconstitute the second. You pay slightly more per milligram of peptide, but you eliminate waste entirely. We've seen research labs cut peptide costs by 30–40% just by switching from bulk vials to study-sized vials.

Kisspeptin isn't a peptide you can store indefinitely once reconstituted. Plan dose count backward from your protocol timeline. Not forward from vial size.

Most peptide protocols fail at the storage stage, not the dosing stage. The 28-day refrigerated stability limit for reconstituted kisspeptin isn't a suggestion. It's the point where HPLC analysis begins detecting measurable degradation in peptide purity. A vial that sat at 2–8°C for 35 days may look identical to one stored for 20 days, but the peptide content has shifted. The difference won't show up in your visual inspection. It shows up in your data as unexplained variability, failed dose-response curves, or results that don't replicate.

Temperature excursions compound the problem. A single overnight excursion above 8°C. Caused by a refrigerator door left ajar or a power interruption. Can denature enough peptide to shift effective concentration by 10–15%. You won't know it happened unless you're monitoring with a continuous temperature logger. The vial still contains liquid. The peptide structure has partially degraded. You're now injecting an unknown dose into your model, and your protocol validity is compromised.

If you're working with research-grade peptides, the quality starts with synthesis. Small-batch production with exact amino-acid sequencing guarantees baseline purity. But synthesis quality means nothing if reconstitution and storage aren't controlled with equal precision. The dose count a vial delivers is only as reliable as the conditions you maintain after opening it.